Pharmacological and Endocrine Effects of Hypericum Perforatum
and Hypericin After Repeated Treatment

 

 Buy Article Permissions and Reprints

Clinical studies have demonstrated the antidepressant efficacy of Hypericum (St. John’s wort) extracts comparable to tricyclic antidepressants such as imipramine. We examined the effects of Hypericum extract and hypericin, one active constituent, in the forced swimming test (FST) after treatment repeated for 14 days. It has recently been shown that hypericin was inactive in the FST after acute treatment, but remarkably active when solubilized by subfraction IIIc₁ containing mainly procyanidin B2. Therefore, we investigated the cooperative effects of hypericin and procyanidin B2 after repeated treatment. Imipramine (15 mg/kg), Hypericum extract (500 mg/kg) and hypericin (0.1 mg/kg) given daily for 2 weeks significantly reduced immobility time in the FST. No differences were observed between animals receiving pure hypericin and those receiving hypericin in combination with procyanidin B2. As several antidepressants act on the neuroendocrine axis resulting in altered hormone concentrations, selected endocrine parameters were investigated after repeated treatment. Daily treatment with either imipramine, Hypericum extract or hypericin alone or in combination with procyanidin B2 for 14 days significantly decreased plasma ACTH and corticosterone levels. None of the substances had pronounced effects on plasma prolactin or LH levels. From our present data, we propose that cooperative effects of hypericin and procyanidin B2 are of important relevance for the acute, but not for the chronic effects of this polycylic quinone.

References

• 1 Betin C F, DeFeudis F, Blavet N, Clostre F. Further characterization of the behavioural despair test in mice: Positive effects of convulsants.  Physiol Behav. 1982;  28 307-311
  CrossrefPubMedGoogle Scholar
• 2 Bhattacharya S, Chakrabarti A, Chatterjee S. Activity profiles of two hyperforin-containing hypericum extracts in behavioral models.  Pharmacopsychiatry. 1998;  31 ( Suppl1) 22-29
  PubMedGoogle Scholar
• 3 Bolton A, Lee-Own V, McLean R, Challend G. Three different radioiodination methods for human spleen ferritin compared.  Clin Chem. 1979;  25 1826-1830
  PubMedGoogle Scholar
• 4 Boyd A, Reichlin S. Neural control of prolactin secretion in man.  Psychoneuroendocrinology. 1978;  3 113-130
  CrossrefPubMedGoogle Scholar
• 5 Brady L, Gold P W, Herkenham M, Lynn A, Whitfield H. The antidepressant fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications.  Brain Res. 1992;  572 117-125
  CrossrefPubMedGoogle Scholar
• 6 Brady L, Whitfield H, Fox R, Gold P W, Herkenham M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase and mineralocorticoid receptor gene expression in rat brain.  J Clin Invest. 1991;  87 831-837
  CrossrefPubMedGoogle Scholar
• 7 Browne R. Effects of antidepressants and anticholinergics in a mouse “behavioural despair” test.  Eur J Pharmacol. 1979;  58 331-334
  CrossrefPubMedGoogle Scholar
• 8 Butterweck V, Wall A, Lieflander-Wulf U, Winterhoff H, Nahrstedt A. Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity.  Pharmacopsychiatry. 1997;  30 ( Suppl2) 117-124
  Article in Thieme ConnectPubMedGoogle Scholar
• 9 Butterweck V, Petereit F, Winterhoff H, Nahrstedt A. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test.  Planta Med. 1998;  64 291-294
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 Butterweck V, Winterhoff H, Herkenham M. Selective effects of long-term administration of St. John’s wort and hypericin on gene transcription in brain areas involved in HPA axis control. Paper submitted 2000
  Google Scholar
• 11 Calapai G, Crupi A, Firenzuoli F, Costantino G, Inferrera G, Campo G, Caputi A. Effects of Hypericum perforatum on levels of 5-hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat.  J Pharm Pharmacol. 1999;  51 723-728
  CrossrefPubMedGoogle Scholar
• 12 Carroll B, Feinberg M, Greden J, Tarika J, Albala A, Haskett R, James N, Kronfol Z, Lohr N, Steiner M, de Vigne J, Young E A. Specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility.  Arch Gen Psychiatry. 1981;  38 15-22
  PubMedGoogle Scholar
• 13 Chatterjee S, Bhattacharya S, Wonnemann M, Singer A, Müller W E. Hyperforin as a possible antidepressant component of hypericum extracts.  Life Sci. 1998;  63 499-510
  CrossrefPubMedGoogle Scholar
• 14 Chung P S, Saxton R E, Paiva M B, Rhee C K, Soudant J, Mathey A, Foote C, Castro D J. Hypericin uptake in rabbits and nude mice transplanted with human squamous cell carcinomas: study of a new sensitizer for laser phototherapy.  Laryngoscope. 1994;  104 1471-1476
  PubMedGoogle Scholar
• 15 Ehrensing R, Kastin A, Schalch D, Friesen H, Vargas J, Schally A. Affective state and thyrotropin and prolactin responses after repeated injections of thyrotropin-releasing hormone in depressed patients.  Am J Psychiatry. 1974;  131 714-718
  PubMedGoogle Scholar
• 16 Foreman M, Doherty P. Experimental approaches for the development of pharmacological therapies for erectile dysfunction. In: Riley, A., M. Peet, C. Wilson (Eds.): Sexual pharmacology Oxford; Oxford Medical Publications 1993: 87-113
• 17 Franklin M, Chi J, McGavin C, Hockney R, Reed A, Campling G, Whale R, Cowen P. Neuroendocrine evidence for dopaminergic actions of Hypericum extract (LI 160) in healthy volunteers.  Biol Psychiatry. 1999;  46 581-584
  CrossrefPubMedGoogle Scholar
• 18 Gold P W, Chrousos G, Kellner C, Post R, Roy A, Augerinos P, Schulte H, Oldfield E, Loriaux D. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor.  Am J Psychiatry. 1984;  141 619-627
  PubMedGoogle Scholar
• 19 Greden J, Gardner R, King D, Grunhaus L, Carroll B, Kronfol Z. Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility.  Arch Gen Psychiatr. 1983;  40 493-500
  PubMedGoogle Scholar
• 20 Gregoire F, Brauman H, De Buck R, Corvilain J. Hormone release in depressed patients before and after recovery.  Psychoneuroendocrinology. 1977;  2 303-312
  CrossrefPubMedGoogle Scholar
• 21 Harrer G, Schulz V. Clinical investigation of the antidepressant effectiveness of hypericum.  J Geriatr Psychiatry Neurol. 1994;  7 S6-S8
  PubMedGoogle Scholar
• 22 Herman J, Brotman A, Pollack M, Falk W, Biederman J, Rosenbaum J. Fluoxetine-induced sexual dysfunction.  J Clin Psychiatry. 1990;  51 25-27
  PubMedGoogle Scholar
• 23 Holsboer F, Liebl R, Hofschuster E. Repeated dexamethasone suppression test during depressive illness. Normalisation of test result compared with clinical improvement.  J Affect Disord. 1982;  4 93-101
  CrossrefPubMedGoogle Scholar
• 24 Holsboer-Trachsler E, Stohler R, Hatzinger M. Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression.  Psychiatry Res. 1991;  38 163-171
  CrossrefPubMedGoogle Scholar
• 25 Kastin A, Scollan E, Ehrensing R, Schally A, Coy D. Enkephalin and other peptides reduce passiveness.  Pharmacol Biochem Behav. 1978;  9 515-519
  CrossrefPubMedGoogle Scholar
• 26 Kellet J. The nature of human sexual desire and its modification by drugs. In: Riley A, Peet M, Wilson C (Eds.) Sexual pharmacology.  Oxford; Oxford Medical Publications 1993: 130-145
  Google Scholar
• 27 Kitada Y, Miyauchi T, Satoh A, Satoh S. Effects of antidepressants in the rat forced swimming test.  Eur J Pharmacol. 1981;  72 145-152
  CrossrefPubMedGoogle Scholar
• 28 Maeda K, Kato Y, Ohgo S, Chihara K, Yoshimoto Y, Yamaguchi N, Kuromaru S, Imura H. Growth hormone and prolactin release after injection of thyrotropin releasing hormone in patients with depression.  J Clin Endocrinol Metabol. 1975;  40 501-505
  PubMedGoogle Scholar
• 29 Müller W, Rolli M, Schäfer C, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity.  Pharmacopsychiatry. 1997;  30 ( Suppl2) 102-107
  Article in Thieme ConnectPubMedGoogle Scholar
• 30 Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L.  Pharmacopsychiatry. 1997;  30 ((Suppl)) 129-134
  PubMedGoogle Scholar
• 31 Ondrizek R, Chan P, Patton W, King A. An alternative medicine study of herbal effects on the penetration of zona-free hamster oocytes and the integrity of sperm deoxyribonucleic acid.  Fertil Steril. 1999;  71 517-522
  CrossrefPubMedGoogle Scholar
• 32 Özturk Y. Testing the antidepressant effects of Hypericum species on animal models.  Pharmacopsychiatry. 1997;  30 ((Suppl)) 125-128
  PubMedGoogle Scholar
• 33 Philipp M, Kohnen R, Hiller K. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks.  Br Med J. 1999;  319 1534-1538
  PubMedGoogle Scholar
• 34 Ploss O. Proanthocyanidine aus dem Kraut von Hypericum perforatum L. Dissertation Universität Muenster 2000
  Google Scholar
• 35 Porsolt R, Anton G, Blavet N, Jalfre M. Behavioural despair in rats: A new model sensitive to antidepressant treatments.  Europ J Pharmacol. 1978;  47 379-391
  CrossrefPubMedGoogle Scholar
• 36 Porsolt R, Le Pichon M, Jalfre M. Depression: A new animal model sensitive to antidepressant treatments.  Nature. 1977;  266 730-732
  PubMedGoogle Scholar
• 37 Porsolt R. Behavioural despair. Raven Press 1981: 121-139
  Google Scholar
• 38 Reul J MHM, Stec I, Söder M, Holsboer F. Chronic treatment of rats with antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system.  Endocrinology. 1993;  133 312-320
  CrossrefPubMedGoogle Scholar
• 39 Rubin R, Phillips J, McCracken J, Sadow T. Adrenal gland volume in major depression: Relationship to basal and stimulated pituitary-adrenal cortical axis function.  Biol Psychiatry. 1996;  40 89-97
  CrossrefPubMedGoogle Scholar
• 40 Rubin R, Phillips J, Sadow T, McCracken J. Adrenal gland volume in major depression: Increase during the depressive episode and decrease with successful treatment.  Arch Gen Psychiatry. 1995;  52 213-218
  PubMedGoogle Scholar
• 41 Simmen U, Burkard W, Berger K, Schaffner W, Lundstrom K. Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system.  J Recept Signal Transduct Res. 1999;  1(19) 59-74
  PubMedGoogle Scholar
• 42 Singer A, Wonnemann M, Müller W. Hyperforin, a major antidepressant constituent of St. John’s Wort, inhibits serotonin uptake by elevating free intracellular Na⁺.  J Pharmacol Exp Ther. 1999;  290 1363-1368
  PubMedGoogle Scholar
• 43 Vogel G, Vogel W. (Eds.) .Drug Discovery and Evaluation. Berlin; Springer Verlag 1997
  Google Scholar
• 44 Volz H. Controlled clinical trials of hypericum extracts in depressed patients- an overview.  Pharmacopsychiatry. 1997;  30 ((Suppl)) 72-76
  PubMedGoogle Scholar
• 45 Wallach M, Hedley L. The effects of antihistmines in a modified behavioural despair test.  Commun Psychopharmacol. 1979;  3 35-39
  PubMedGoogle Scholar
• 46 Wheatly D. Hypericum extract-potential in the treatment of depression.  CNS Drugs. 1998;  9 431-440
  PubMedGoogle Scholar
• 47 Winterhoff H, Butterweck V, Nahrstedt A, Gumbinger H, Schulz V, Erping S, Bosshammer F, Wieligmann A. Pharmakologische Untersuchungen zur antidepressiven Wirkung von Hypericum perforatum L. In: Loew D, Rietbrock N (Eds.) Phytopharmaka in Forschung und klinischer Anwendung. Darmstadt; Steinkopff Verlag 1995: 39-56
  Google Scholar
• 48 Yells D, Prendergast M, Hendricks S, Nakamura M. Fluoxetine-induced inhibition of male copulatory behaviour: Modification by lesions of the nucleus paragigantocellularis.  Pharmacol Biochem Behav. 1994;  49 121-127
  CrossrefPubMedGoogle Scholar

Dr. Veronika Butterweck

Institut für Pharmakologie und Toxikologie

Domagkstraße 12

48149 Münster

Germany

Email: butterv@uni-muenster.de